Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, parallel-group, single-dose study of the PK and safety of 400 mg
pacritinib administered orally to patients with stable chronic liver disease and healthy
control subjects.